Arcutis Biotherapeutics, Inc. (ARQT) is a publicly traded company in the Unknown sector. Across all available filings, 30 corporate insiders have executed 520 transactions totaling $120.3M, demonstrating a bullish sentiment with $22.2M in net insider flow. The most recent transaction on Feb 4, 2026 involved a sale of 9,794 shares valued at $252.7K.
No significant insider buying has been recorded for ARQT in the recent period.
No significant insider selling has been recorded for ARQT in the recent period.
Based on recent SEC filings, insider sentiment for ARQT is bullish with an Insider Alignment Score of 59/100 and a net flow of $22.2M. Insiders are accumulating shares, which historically signals confidence in the company's future performance.
Insider trading at Arcutis Biotherapeutics, Inc. (ARQT) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 30 insiders are actively trading ARQT stock, having executed 520 transactions in the past 90 days. The most active insider is Capital Llc Orbimed (Executive), who has made 11 transactions totaling $27.7M.
Get notified when executives and directors at ARQT file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 4, 2026 | Burnett Patrick | See Remarks | Sale | 9,794 | $25.81 | $252.7K | |
| Feb 2, 2026 | Todd Edwards Larry | See Remarks | Sale | 2,052 | $25.50 | $52.3K | |
| Feb 2, 2026 | G. Welgus Howard | Executive | Sale | 10,000 | $25.05 | $250.5K | |
| Feb 2, 2026 | Vairavan Latha | SVP Chief Financial Officer | Sale | 1,320 | $25.50 | $33.7K | C-Suite |
| Feb 2, 2026 | Watanabe Todd | Executive | Sale | 19,833 | $25.50 | $505.7K | Large |
| Feb 2, 2026 | Burnett Patrick | See Remarks | Sale | 3,675 | $25.50 | $93.7K | |
| Jan 5, 2026 | Burnett Patrick | See Remarks | Sale | 2,490 | $28.98 | $72.2K | |
| Jan 2, 2026 | G. Welgus Howard | Executive | Sale | 10,000 | $28.96 | $289.6K | |
| Dec 15, 2025 | Burnett Patrick | Executive | Option Exercise | 11,500 | $3.64 | $41.9K | |
| Dec 15, 2025 | Burnett Patrick | Executive | Sale | 11,500 | $28.94 | $332.8K | |
| Dec 4, 2025 | Munshi Amit | Executive | Award | 2,021 | $N/A | $0 | |
| Dec 1, 2025 | G. Welgus Howard | Executive | Sale | 10,000 | $30.21 | $302.1K | |
| Dec 1, 2025 | Matsuda Masaru | Executive | Sale | 1,657 | $30.23 | $50.1K | |
| Nov 24, 2025 | Watanabe Todd | Executive | Sale | 48,945 | $30.36 | $1.5M | Large |
| Nov 24, 2025 | Lin Sue-jean | Executive | Option Exercise | 7,220 | $7.51 | $54.2K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Purchase(P) | 15 | $71.2M | 58.3% |
Sale(S) | 259 | $49.0M | 40.1% |
Exercise(M) | 121 | $1.7M | 1.4% |
Award(A) | 94 | $214.0K | 0.2% |
Gift(G) | 7 | $0 | 0.0% |
Other(J) | 4 | $0 | 0.0% |
Conversion(C) | 20 | $0 | 0.0% |
Insider activity at Arcutis Biotherapeutics, Inc. shows mixed signals across all time. While $71.2M in purchases indicates some executive confidence,$49.0M in sales balances the picture, resulting in a modest net flow of $22.2M.30 insiders have been active, with no strong directional conviction evident in the aggregate data. The most active insider, Capital Llc Orbimed, has transacted $27.7M during this period.